The cardiovascular polypill in high-risk patients

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Atherosclerotic cardiovascular diseases are a leading global cause of death.
• Effective management of vascular risk factors like LDL cholesterol and blood pressure is crucial.
• Significant treatment gaps persist in high-risk populations requiring multiple medications.

Observation:

• The cardiovascular polypill, a fixed-dose combination of aspirin, statin, and blood-pressure lowering agents, has been proposed to improve adherence and reduce cardiovascular disease risk.
• A decade of recommendations has passed since the development and trial of polypills.
• Debate continues regarding the optimal initial target population for polypill implementation.

Findings:

• This review examines the role of fixed-dose combination therapy in various patient groups, detailing its advantages and disadvantages.
• Current and planned trials for cardiovascular polypills are summarized.
• Evidence is emerging for the efficacy of polypills in high-risk populations, particularly with affordable, off-patent medications.

Implications:

• The polypill strategy holds promise for enhancing cardiovascular disease prevention in both primary and secondary settings.
• Affordable, fixed-dose combination pills can potentially bridge treatment gaps and improve patient outcomes.
• Further trials and implementation strategies are needed to realize the full potential of polypills in public health.